98%
921
2 minutes
20
Background: Our goal is to develop a nomogram model to predict overall survival (OS) for elderly esophageal squamous cell carcinoma (ESCC) patients receiving definitive radiotherapy (RT) or concurrent chemoradiotherapy (CRT), aiding clinicians in personalized treatment planning with a risk stratification system.
Methods: A retrospective study was conducted on 718 elderly ESCC patients treated with RT or CRT at 10 medical centers (3JECROG) from January 2004 to November 2016. We identified independent prognostic factors using univariate and multifactorial Cox regression to construct a nomogram model. Its effectiveness was evaluated using concordance statistics (C-index), area under the curve (AUC), net reclassification index (NRI), and integrated discrimination improvement (IDI), and compared against the AJCC staging. Additionally, decision curve analysis (DCA) assessed the model's clinical benefit. Patients were stratified into low, intermediate, and high-risk groups using the nomogram, and their prognoses in various disease stages were analyzed.
Results: Significant prognostic factors identified included diabetes, tumor volume (GTVp), tumor length, location, and clinical stages (T, N, M), and RT response. Multivariate analysis confirmed these as independent factors for OS. The nomogram outperformed AJCC staging in prediction accuracy and discrimination, evidenced by a higher C-index, better AUC, and significant NRI and IDI values. Patients categorized by the nomogram demonstrated distinct 5-year OS rates, with a higher C-index than AJCC staging (0.597 vs. 0.562) .
Conclusions: The study identified key prognostic factors for elderly ESCC patients receiving RT or CRT. The nomogram model, based on these factors, showed enhanced prediction performance, discrimination, and clinical utility compared to AJCC staging. This risk stratification provided more accurate survival predictions and aided in personalized risk management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11708294 | PMC |
http://dx.doi.org/10.1186/s12885-024-13414-z | DOI Listing |
Ann Surg Oncol
September 2025
Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
Front Endocrinol (Lausanne)
September 2025
Department of General Surgery (Thyroid Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Objective: Poorly differentiated thyroid cancer (PDTC) is a rare, heterogeneous carcinoma from follicular cells, characterized by poor differentiation, aggressive spread, and poor prognosis. Currently, there is no specific staging system for PDTC. This study aimed to develop a new TNM staging system tailored to PDTC for improved disease management.
View Article and Find Full Text PDFUrol Oncol
September 2025
Department of Urology, UC San Diego School of Medicine, La Jolla, USA; Department of Urology, Rush Universtiy Medical Center, Chicago, USA. Electronic address:
Objective: Outcomes of stage 1 renal cell carcinoma (RCC) are heterogeneous and vary widely. We sought to investigate whether tripartite reclassification of current binary T1 RCC would lead to more rational consolidation of similar outcomes that may improve predictive ability.
Methods: We performed a retrospective multicenter analysis of patients undergoing radical (RN) or partial nephrectomy (PN) for clinical T1N0M0 RCC.
Einstein (Sao Paulo)
September 2025
Internal Medicine Department, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista "Júlio de Mesquita Filho", Botucatu, SP, Brazil.
Objective: To evaluate whether the total tumor diameter (sum of the largest diameters of all foci) predicts tumor aggressiveness at initial presentation and treatment response at 1-year follow-up in patients with multifocal papillary thyroid microcarcinoma.
Methods: A retrospective analysis was conducted on 475 patients with differentiated thyroid carcinoma. Fifty-two patients with multifocal papillary thyroid microcarcinoma were included.
PeerJ
September 2025
Department of Thyroid Surgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Background: The occurrence of thyroid carcinoma in patients with Graves' disease (GD) has been rising recently. However, the linkage between lipids and the incidence of thyroid carcinoma among GD patients is still not well-established.
Objective: The research aims to explore the relationship between serum lipid concentrations and the occurrence of thyroid cancer in patients diagnosed with GD.